article thumbnail

Assessment of Project ECHO(R) Opioid Use Disorder Sessions for Primary Care Teams [Education and training]

Annals of Family Medicine

Intervention: 12 monthly online OUD sessions held from April 2023 to March 2024. 4 expert faculty members developed session curriculum: screening and diagnosis, using behavioral health/counseling, addressing harm reduction, among others. Setting: 20 PC practices located in various regions across the US.

article thumbnail

Pain-Related Medication in Adults with Intellectual Disability: a systematic review [Pain management]

Annals of Family Medicine

Objective: To synthesize literature on pain-related medication in adults with ID and examine how it relates to MLTCs and polypharmacy and explore the views of adults with ID, caregivers and healthcare providers on pain medication use. There was over-prescribing of antipsychotic medication without an associated diagnosis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The utilization patterns and impact of the Stanford Chronic Pain Self-Management Program in Eastern Ontario, Canada [Pain management]

Annals of Family Medicine

Context Healthcare providers often struggle to treat patients with chronic pain. Dataset: We used data routinely collected through the CPSMP between December 2017 and May 2023. Anyone suffering from pain could register for the program without needing a referral or formal diagnosis from a health care practitioner.

article thumbnail

AMPLIFY™ Technology Enhances Prenatal Screening for 22q11.2 Microdeletion

Myriad Genetics

4 In a recent presentation, Dale Muzzey, PhD, Chief Scientific Officer at Myriad, summarized the findings this way: “We followed up with providers regarding their patients who screened positive for 22q. 5 Clear Benefits for Healthcare Providers and Patients The benefits to a high PPV are, well, myriad. Published 2023 Jan 6.

article thumbnail

AI/ML-enabled Medical Devices Have Everyone’s Attention, Including FDA’s

FDA Law

discusses several approaches that companies are exploring for use of AI in the diagnosis of Alzheimer’s Disease, including AI-enabled software for retinal scans and identification of genetic triggers. The first article—“Is the Eye the Window to Alzheimer’s?”—discusses Meanwhile, FDA’s AI/ML-focused initiatives continue to expand.

Medical 119
article thumbnail

Prescribing Red Flags and Suspicious Controlled Substance Orders: Current Cautionary Tales

FDA Law

Houck — Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing or distributing controlled substances. 11, 2023 ( DOJ Press Release ). 6, 2023 ( DOJ Press Release ). By Larry K. Complaint ¶ 60. Complaint ¶ 61.

article thumbnail

Proposed LDT Rule Raises Many Questions but Provides Few Answers

FDA Law

The amended regulation would read as follows (revisions underlined): In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.